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Abstract 
Human rhinovirus (RV) infections are the principle cause of common colds and precipitate 
asthma and chronic obstructive pulmonary disease (COPD) exacerbations. Currently there is 
no vaccine for RV which is largely due to the existence of ~160 serotypes/strains. We 
demonstrated previously that immunising mice with highly conserved VP4 and VP2 regions 
of the RV polyprotein (RV-A16 VP0) generated cross-reactive immunity to RV in vivo. The 
current study investigated and mapped the epitopes of RV-A16 VP0 that are targets for 
antibodies in serum samples from VP0 immunisation and RV challenge studies in mice. 
Recombinant capsid proteins, peptide pools and individual peptides spanning the immunogen 
sequence (RV-A16 VP0) were assessed for IgG binding sites to identify epitopes. We found 
that peptide pools covering the C-terminus of VP4, the N-terminus of VP2 and the neutralising 
NIm-II site within VP2 were bound by serum IgG from immunised mice. The NIm-II site 
peptide pool blocked IgG binding to the immunogen RV-A16 VP0 and individual peptides 
within the pool binding IgG were further mapped. Thus, we have identified immunodominant 
epitopes of RV vaccine candidate RV-A16 VP0, noting that strong IgG binding antibodies 
were observed that target a key neutralising epitope that is highly variable amongst RV 
serotypes. 
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